Jellatech, a biotechnology company specializing in sustainable protein production, recently announced the successful opening of a new 9,000-square-foot research and development facility in Morrisville, North Carolina. This space, intended to achieve GLP (Good Laboratory Practice) certification by 2026, represents a strategic step in Jellatech’s growth, focusing on scaling bio-identical collagen production to meet demand across various industries while maintaining ethical and sustainable practices.
Founded in 2020, Jellatech has dedicated itself to producing bio-identical collagen—a protein that mimics naturally occurring collagen without relying on animal sources. Collagen plays a vital role in the structural integrity of skin, bones, and connective tissues and is widely used in healthcare, cosmetics, and regenerative medicine. Jellatech’s approach to creating bio-identical collagen via cellular agriculture aims to address industry challenges around supply, ethical sourcing, and environmental sustainability.
The company’s innovation aligns with growing market interest in alternative protein sources. Bio-identical collagen, created through cellular technology, allows industries to bypass conventional animal-derived sources, reducing environmental impact and avoiding the supply chain complexities often associated with animal-based production.
The new Morrisville facility is designed with advanced capabilities to support Jellatech’s goal of producing bio-identical proteins at a scale that meets regulatory standards. Key features include state-of-the-art bioreactors for efficient protein production, cell line development labs, and areas dedicated to quality control processes essential for meeting the strict requirements of the biomedical and pharmaceutical industries.
One of the primary aims of the facility is to support product validation and enable clients to advance into pre-clinical trials. The expanded infrastructure allows Jellatech to optimize cell line development and improve consistency, addressing critical requirements for scaling collagen-based applications in regenerative healthcare, cosmetic formulations, and biostimulatory treatments. This increased capacity also supports Jellatech in meeting the stringent quality and regulatory needs essential for products intended for human health applications.
The global collagen market is anticipated to grow steadily, driven by demand in diverse sectors like healthcare, beauty, and food. Jellatech’s approach to collagen production through cellular agriculture addresses significant industry pain points, such as resource-intensive supply chains and quality inconsistencies in animal-derived collagen. By focusing on bio-identical collagen, Jellatech seeks to support sustainable, high-quality solutions for sectors that prioritize purity and performance, such as biomedical and pharmaceutical industries, where biostimulatory and regenerative solutions are in high demand.
To achieve GLP certification by 2026, Jellatech’s facility is built to accommodate future growth in production capacity and regulatory compliance. This will enable the company to meet expanding demand as collagen-based applications gain traction in both established and emerging markets. In addition to in-house production, Jellatech plans to foster partnerships with industry leaders to support collaborative research and development. These alliances will focus on biostimulatory and regenerative applications, potentially driving further innovation in the field of cellular agriculture.
Jellatech’s expansion has been supported by multiple funding rounds, reflecting investor interest in sustainable biotechnology and cellular agriculture. In 2021, Jellatech completed a seed funding round led by prominent venture capital firms in the biotech space, which enabled the development of foundational technology and initial lab facilities. A follow-up Series A round in 2023 raised additional capital to support this latest facility expansion, underscoring investor confidence in Jellatech’s approach to sustainable protein production. The funds have been instrumental in equipping the new facility, advancing research, and pursuing regulatory milestones.
As Jellatech continues to expand its production capabilities and regulatory reach, the company is positioned to contribute meaningfully to the growing field of sustainable biotechnology. The Morrisville facility marks a key step in Jellatech’s roadmap, focusing on consistent and scalable production that meets the rigorous demands of industries looking to adopt alternative protein sources. This facility is expected to become a central hub for both product development and collaborative industry partnerships, reinforcing Jellatech’s commitment to high-quality, ethical, and sustainable protein production.
Commenti